Prime Medicine, Inc. (NYSE:PRME – Get Rating) was down 4% on Wednesday after an insider sold shares in the company. The company traded as low as $14.59 and last traded at $14.59. Approximately 12,119 shares changed hands during trading, a decline of 95% from the average daily volume of 241,851 shares. The stock had previously closed at $15.20.
Specifically, major shareholder 2019 Gp L.L.C. Gv sold 87,922 shares of Prime Medicine stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $14.13, for a total value of $1,242,337.86. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 214,686 shares of company stock valued at $3,120,408. Corporate insiders own 24.29% of the company’s stock.
Analyst Ratings Changes
Separately, StockNews.com upgraded Prime Medicine to a “sell” rating in a report on Tuesday, May 23rd.
Prime Medicine Stock Performance
About Prime Medicine
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Further Reading
- Get a free research report on Prime Medicine from StockNews.com
- Smartsheet Investors’ Hasty Exit Can Be Your Gain
- Agilent Technologies Stock: Ready to Rise off the Floor
- Oilfield Services Growing Faster Than Wider Energy Sector
- La-Z-Boy Reclines To The Buy Zone As Industry Normalizes
- Five stocks we like better than Prime Medicine
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
